Parkinson's researchers might be chasing the wrong culprit

03/21/2013 | Bloomberg

Alnylam Pharmaceuticals, Elan, NeuroPhage Pharmaceuticals and Prana Biotechnology are among the drugmakers developing therapies that focus on reducing alpha-synuclein in the brains of Parkinson's disease patients, but new research associates low levels of the protein with worsening symptoms. Parkinson's patients who had the lowest production of alpha-synuclein had a 23% higher risk of developing dementia or becoming disabled than patients with the highest levels, researchers reported at an American Academy of Neurology meeting.

View Full Article in:

Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT